# A022004 (NCT05710406)

> Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05710406
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Alliance for Clinical Trials in Oncology
- Conditions: Colon Adenocarcinoma; Microsatellite Stable Colon Carcinoma; Stage IIB Colon Cancer AJCC v8; Stage IIC Colon Cancer AJCC v8; Stage III Colon Cancer AJCC v8
- Interventions: Encorafenib; Cetuximab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Patient Observation
- Enrollment: 1
- Primary outcome: Circulating tumor deoxyribonucleic acid (ctDNA) clearance rate (Phase II; ctDNA positive cohort)
- Primary outcome: tDNA recurrence-free survival rate (ctDNA-RFS) (Phase II; ctDNA negative cohort)
- Primary outcome: Disease free survival (DFS) (Phase III)

## Indexed commentary on A022004 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=a022004-nct05710406

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05710406", "email": "<work email>"}; the inbox owner confirms by the emailed link.